Article Details

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market to Witness Robust Expansion by 2029

Retrieved on: 2022-04-14 12:25:55

Tags for this article:

Click the tags to see associated articles and topics

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market to Witness Robust Expansion by 2029. View article details on hiswai:

Excerpt

F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals, RemeGen, Nihon Pharmaceutical, Harbour BioMed, Lundbeck, Bionure, Opexa Therapeutics, ...

Article found on: blackswanzine.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up